NCT03816553View on ClinicalTrials.gov

SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 19, 2019

Primary Completion Date

April 30, 2020

Study Completion Date

August 31, 2022

Conditions
Recurrent Cervical CarcinomaMetastatic Cervical Cancer
Interventions
DRUG

SHR-1210

SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg (3mg/kg for underweight patients).

DRUG

Apatinib

Apatinib will be administered 250mg orally, once daily until progression.

Trial Locations (3)

510060

Sun Yat-sen University Cancer Center, Guangzhou

510080

The First affiliated Hospital of Sun Yat-sen University, Guanzhou

511400

Guangzhou Panyu Central Hospital, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT03816553 - SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer | Biotech Hunter | Biotech Hunter